ReviewCureus2022
Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- An Antimicrobial susceptibility study to compare the in vitro activity of antimicrobial agents in the Philippines against Enterobacterales and Pseudomonas aeruginosa from different infection sites: results from ATLAS surveillance program (2018-2021).BMC infectious diseases · 2026Article
- Bioactive Compounds, Antioxidant, and Antibacterial Activity Against MDR and Food-Borne Pathogenic Bacteria of Psidium guajava. L Fruit During Ripening.Molecular biotechnology · 2025Article
- Evaluating the susceptibility to ceftazidime-avibactam in clinical isolates ofIranian journal of microbiology · 2025Article
- Investigating Gram-negative bacilli isolates' sensitivity to ceftazidime/avibactam.Journal of family medicine and primary care · 2025Article
- Role of Ceftazidime-Avibactam in Urinary Tract Infections Caused by Carbapenem-Resistant Enterobacterales.Cureus · 2024Article
- Sepsis Stewardship: The Puzzle of Antibiotic Therapy in the Context of Individualization of Decision Making.Journal of personalized medicine · 2024Review
- Antibacterial activities, PASS prediction and ADME analysis of phytochemicals fromIn silico pharmacology · 2024Article
- Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-ResistantCritical care research and practice · 2024Article
- Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-PositiveInfection and drug resistance · 2024Article
- Article
- Detection of Inflammatory Biomarkers Among Patients with Sepsis of Gram-Negative Bacteria: A Cross-Sectional Study.International journal of general medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of antibiotic-resistant pathogens exerts a substantial burden on the healthcare infrastructure worldwide. The World Health Organization (WHO) has declared that multidrug-resistant (MDR) Gram-negative pathogens, especially, carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.